At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMNN Imunon, Inc.
Market Closed 04-24 16:00:00 EDT
2.79
-0.07
-2.45%
盘后2.79
+0.000.00%
16:10 EDT
High2.90Low2.74Vol19.86K
Open2.87D1 Closing2.86Amplitude5.59%
Mkt Cap10.94MTradable Cap9.87MTotal Shares3.92M
T/O56.48KT/O Rate0.56%Tradable Shares3.54M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Imunon Initiated at Buy by Maxim Group
Dow Jones  ·  04-17
Imunon Initiated at Buy by Maxim Group
Imunon initiated with a Buy at Maxim
TIPRANKS  ·  04-17
Imunon initiated with a Buy at Maxim
Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)
TIPRANKS  ·  04-02
Analysts Offer Insights on Healthcare Companies: Imunon (IMNN), Axsome Therapeutics (AXSM) and Oric Pharmaceuticals (ORIC)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Imunon (IMNN) and Novo Nordisk (NVO)
TIPRANKS  ·  04-01
Analysts Have Conflicting Sentiments on These Healthcare Companies: Imunon (IMNN) and Novo Nordisk (NVO)
Imunon FY25 net loss narrows 22% to $14.5 million; cash climbs to $8.8 million
Reuters  ·  04-01
Imunon FY25 net loss narrows 22% to $14.5 million; cash climbs to $8.8 million
BRIEF-Imunon Reports 2025 Financial Results And Provides Business Update
Reuters  ·  03-31
BRIEF-Imunon Reports 2025 Financial Results And Provides Business Update
Imunon Q4 EPS $(1.30) Misses $(1.13) Estimate
Benzinga  ·  03-31
Imunon Q4 EPS $(1.30) Misses $(1.13) Estimate
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  03-30
Calendar of U.S. Earnings Expected in the Week Ahead
Imunon Inc expected to post a loss of $1.17 a share - Earnings Preview
Reuters  ·  03-27
Imunon Inc expected to post a loss of $1.17 a share - Earnings Preview
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  03-27
Calendar of U.S. Earnings Expected in the Week Ahead
BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
Reuters  ·  03-26
BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
Imunon announces final clinical data from OVATION 2 clinical trial
TIPRANKS  ·  03-25
Imunon announces final clinical data from OVATION 2 clinical trial
Imunon: Patients Treated With Parp Inhibitor Therapy With Imnn-001 & Standard of Care Chemotherapy Showed Median Increase in Os of 24.2 Mnths
THOMSON REUTERS  ·  03-25
Imunon: Patients Treated With Parp Inhibitor Therapy With Imnn-001 & Standard of Care Chemotherapy Showed Median Increase in Os of 24.2 Mnths
Imunon Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival With Imnn-001 in Women With Newly Diagnosed Advanced Ovarian Cancer
THOMSON REUTERS  ·  03-25
Imunon Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival With Imnn-001 in Women With Newly Diagnosed Advanced Ovarian Cancer
Imunon: Rise in Median Overall Survival Among Women Treated With Imnn-001 in Ovation 2 Trial Rose From 11.1 Mnths to 14.7 Mnths
THOMSON REUTERS  ·  03-25
Imunon: Rise in Median Overall Survival Among Women Treated With Imnn-001 in Ovation 2 Trial Rose From 11.1 Mnths to 14.7 Mnths
Imunon reports Phase 2 OVATION 2 data; median overall survival rises by 14.7 months with IMNN-001 in newly diagnosed advanced ovarian cancer
Reuters  ·  03-25
Imunon reports Phase 2 OVATION 2 data; median overall survival rises by 14.7 months with IMNN-001 in newly diagnosed advanced ovarian cancer
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  03-25
Calendar of U.S. Earnings Expected in the Week Ahead
Imunon to host year-end 2025 financial results conference call
Reuters  ·  03-24
Imunon to host year-end 2025 financial results conference call
Imunon files prospectus supplement for USD 7 million at-the-market common stock offering
Reuters  ·  03-24
Imunon files prospectus supplement for USD 7 million at-the-market common stock offering
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  03-23
Calendar of U.S. Earnings Expected in the Week Ahead
No data available

Introduction

Company Name.
Imunon, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Issue price:
--